Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

NeuroPace (NPCE) Shares Outstanding (2020 - 2026)

NeuroPace has reported Shares Outstanding over the past 7 years, most recently at $33.9 million for Q1 2026.

  • For Q1 2026, Shares Outstanding rose 3.54% year-over-year to $33.9 million; the TTM value through Mar 2026 reached $33.9 million, up 3.54%, while the annual FY2025 figure was $33.6 million, 11.38% up from the prior year.
  • Shares Outstanding for Q1 2026 was $33.9 million at NeuroPace, up from $33.6 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $33.9 million in Q1 2026 and troughed at $24.5 million in Q1 2022.
  • A 5-year average of $28.8 million and a median of $28.7 million in 2024 define the central range for Shares Outstanding.
  • On a YoY basis, Shares Outstanding climbed as much as 5100.89% in 2022 and fell as far as 2.14% in 2022.
  • Year by year, Shares Outstanding stood at $25.0 million in 2022, then rose by 11.09% to $27.8 million in 2023, then increased by 8.34% to $30.1 million in 2024, then grew by 11.38% to $33.6 million in 2025, then rose by 1.0% to $33.9 million in 2026.
  • Business Quant data shows Shares Outstanding for NPCE at $33.9 million in Q1 2026, $33.6 million in Q4 2025, and $33.3 million in Q3 2025.